Search Results - "SCHIMMER, Aaron D"

What doesn’t kill you makes you stronger – bcl-2 promotes survival independent of proliferation by Schimmer, Aaron D.

Get full text

Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality by Ishizawa, Jo, Zarabi, Sarah F., Davis, R. Eric, Halgas, Ondrej, Nii, Takenobu, Jitkova, Yulia, Zhao, Ran, St-Germain, Jonathan, Heese, Lauren E., Egan, Grace, Ruvolo, Vivian R., Barghout, Samir H., Nishida, Yuki, Hurren, Rose, Ma, Wencai, Gronda, Marcela, Link, Todd, Wong, Keith, Mabanglo, Mark, Kojima, Kensuke, Borthakur, Gautam, MacLean, Neil, Ma, Man Chun John, Leber, Andrew B., Minden, Mark D., Houry, Walid, Kantarjian, Hagop, Stogniew, Martin, Raught, Brian, Pai, Emil F., Schimmer, Aaron D., Andreeff, Michael

“…The mitochondrial caseinolytic protease P (ClpP) plays a central role in mitochondrial protein quality control by degrading misfolded proteins. Using genetic…”
Get full text

Inhibition of Mitochondrial Translation as a Therapeutic Strategy for Human Acute Myeloid Leukemia by Škrtić, Marko, Sriskanthadevan, Shrivani, Jhas, Bozhena, Gebbia, Marinella, Wang, Xiaoming, Wang, Zezhou, Hurren, Rose, Jitkova, Yulia, Gronda, Marcela, Maclean, Neil, Lai, Courteney K., Eberhard, Yanina, Bartoszko, Justyna, Spagnuolo, Paul, Rutledge, Angela C., Datti, Alessandro, Ketela, Troy, Moffat, Jason, Robinson, Brian H., Cameron, Jessie H., Wrana, Jeffery, Eaves, Connie J., Minden, Mark D., Wang, Jean C.Y., Dick, John E., Humphries, Keith, Nislow, Corey, Giaever, Guri, Schimmer, Aaron D.

“…To identify FDA-approved agents targeting leukemic cells, we performed a chemical screen on two human leukemic cell lines and identified the antimicrobial…”
Get full text

Novel Proteasome Inhibitors to Overcome Bortezomib Resistance by Ruschak, Amy M., Slassi, Malik, Kay, Lewis E., Schimmer, Aaron D.

“…The proteasome is an intracellular enzyme complex that degrades ubiquitin-tagged proteins and thereby regulates protein levels within the cell. Given this…”
Get full text

Very long chain fatty acid metabolism is required in acute myeloid leukemia by Tcheng, Matthew, Roma, Alessia, Ahmed, Nawaz, Smith, Richard W., Jayanth, Preethi, Minden, Mark D., Schimmer, Aaron D., Hess, David A., Hope, Kristin, Rea, Kevin A., Akhtar, Tariq A., Bohrnsen, Eric, D'Alessandro, Angelo, Mohsen, Al-Walid, Vockley, Jerry, Spagnuolo, Paul A.

“…Acute myeloid leukemia (AML) cells have an atypical metabolic phenotype characterized by increased mitochondrial mass, as well as a greater reliance on…”
Get full text

MTCH2-mediated mitochondrial fusion drives exit from naïve pluripotency in embryonic stem cells by Bahat, Amir, Goldman, Andres, Zaltsman, Yehudit, Khan, Dilshad H., Halperin, Coral, Amzallag, Emmanuel, Krupalnik, Vladislav, Mullokandov, Michael, Silberman, Alon, Erez, Ayelet, Schimmer, Aaron D., Hanna, Jacob H., Gross, Atan

“…The role of mitochondria dynamics and its molecular regulators remains largely unknown during naïve-to-primed pluripotent cell interconversion. Here we report…”
Get full text

Mitochondrial and Metabolic Pathways Regulate Nuclear Gene Expression to Control Differentiation, Stem Cell Function, and Immune Response in Leukemia by Egan, Grace, Khan, Dilshad H, Lee, Jong Bok, Mirali, Sara, Zhang, Li, Schimmer, Aaron D

“…Mitochondria are involved in many biological processes including cellular homeostasis, energy generation, and apoptosis. Moreover, mitochondrial and metabolic…”
Get more information

Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia by Cole, Alicia, Wang, Zezhou, Coyaud, Etienne, Voisin, Veronique, Gronda, Marcela, Jitkova, Yulia, Mattson, Rachel, Hurren, Rose, Babovic, Sonja, Maclean, Neil, Restall, Ian, Wang, Xiaoming, Jeyaraju, Danny V., Sukhai, Mahadeo A., Prabha, Swayam, Bashir, Shaheena, Ramakrishnan, Ashwin, Leung, Elisa, Qia, Yi Hua, Zhang, Nianxian, Combes, Kevin R., Ketela, Troy, Lin, Fengshu, Houry, Walid A., Aman, Ahmed, Al-awar, Rima, Zheng, Wei, Wienholds, Erno, Xu, Chang Jiang, Dick, John, Wang, Jean C.Y., Moffat, Jason, Minden, Mark D., Eaves, Connie J., Bader, Gary D., Hao, Zhenyue, Kornblau, Steven M., Raught, Brian, Schimmer, Aaron D.

“…From an shRNA screen, we identified ClpP as a member of the mitochondrial proteome whose knockdown reduced the viability of K562 leukemic cells. Expression of…”
Get full text

Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia by Barghout, Samir H., Patel, Parasvi S., Wang, Xiaoming, Xu, G. Wei, Kavanagh, Simon, Halgas, Ondrej, Zarabi, Sara F., Gronda, Marcela, Hurren, Rose, Jeyaraju, Danny V., MacLean, Neil, Brennan, Shawn, Hyer, Marc L., Berger, Allison, Traore, Tary, Milhollen, Michael, Smith, Adam C., Minden, Mark D., Pai, Emil F., Hakem, Razq, Schimmer, Aaron D.

“…Acute myeloid leukemia (AML) is an aggressive hematologic malignancy for which new therapeutic approaches are required. One such potential therapeutic strategy…”
Get full text

A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia by Schimmer, Aaron D, Raza, Azra, Carter, Thomas H, Claxton, David, Erba, Harry, DeAngelo, Daniel J, Tallman, Martin S, Goard, Carolyn, Borthakur, Gautam

“…An open-label phase I/II study of single-agent obatoclax determined a maximum tolerated dose (MTD) and schedule, safety, and efficacy in older patients (≥ 70…”
Get full text

RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs by Robinson, Tyler J W, Liu, Jeff C, Vizeacoumar, Frederick, Sun, Thomas, Maclean, Neil, Egan, Sean E, Schimmer, Aaron D, Datti, Alessandro, Zacksenhaus, Eldad

“…Triple negative breast cancer (TNBC) includes basal-like and claudin-low subtypes for which only chemotherapy and radiation therapy are currently available…”
Get full text

The ubiquitin-activating enzyme, UBA1, as a novel therapeutic target for AML by Barghout, Samir H, Schimmer, Aaron D

Get full text

Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma by Saha, Manujendra N, Jiang, Hua, Yang, Yijun, Zhu, Xiaoyun, Wang, Xiaoming, Schimmer, Aaron D, Qiu, Lugui, Chang, Hong

“…The low frequency of p53 alterations e.g., mutations/deletions (∼10%) in multiple myeloma (MM) makes this tumor type an ideal candidate for p53-targeted…”
Get full text

Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase by Jeyaraju, Danny V, Alapa, Maryam, Polonskaia, Ann, Risueño, Alberto, Subramanyam, Prakash, Anand, Amit, Ghosh, Kaushik, Kyriakopoulos, Charalampos, Hemerich, Daiane, Hurren, Rose, Wang, Xiaoming, Gronda, Marcela, Ahsan, Aarif, Chiu, Hsiling, Thomas, Geethu, Lind, Evan F, Menezes, Daniel L, Schimmer, Aaron D, Hagner, Patrick R, Gandhi, Anita, Thakurta, Anjan G

“…Oral azacitidine (oral-Aza) treatment results in longer median overall survival (OS) (24.7 vs. 14.8 months in placebo) in patients with acute myeloid leukemia…”
Get full text

Biological and therapeutic implications of a unique subtype of NPM1 mutated AML by Mer, Arvind Singh, Heath, Emily M., Madani Tonekaboni, Seyed Ali, Dogan-Artun, Nergiz, Nair, Sisira Kadambat, Murison, Alex, Garcia-Prat, Laura, Shlush, Liran, Hurren, Rose, Voisin, Veronique, Bader, Gary D., Nislow, Corey, Rantalainen, Mattias, Lehmann, Soren, Gower, Mark, Guidos, Cynthia J., Lupien, Mathieu, Dick, John E., Minden, Mark D., Schimmer, Aaron D., Haibe-Kains, Benjamin

“…In acute myeloid leukemia (AML), molecular heterogeneity across patients constitutes a major challenge for prognosis and therapy. AML with NPM1 mutation is a…”
Get full text

Correction: The Natural Pesticide Dihydrorotenone Induces Human Plasma Cell Apoptosis by Triggering Endoplasmic Reticulum Stress and Activating p38 Signaling Pathway by Zhang, Jieyu, Tang, Juan, Cao, Biyin, Zhang, Zubin, Li, Jie, Schimmer, Aaron D, He, Sudan, Mao, Xinliang

“…Human plasma cell lines LP1, OPM2, KMS11 and U266 were treated with DHR for 24 h. Induction of apoptosis in human plasma cells by DHR was assessed by Annexin…”
Get full text

Cyclic AMP‐hydrolyzing phosphodiesterase inhibitors potentiate statin‐induced cancer cell death by Longo, Joseph, Pandyra, Aleksandra A., Stachura, Paweł, Minden, Mark D., Schimmer, Aaron D., Penn, Linda Z.

“…Dipyridamole, an antiplatelet drug, synergizes with statins to induce tumor‐specific apoptosis. Here, we took a pharmacological approach to dissect the…”
Get full text

Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML by Chiu, May, Schimmer, Aaron D., Schuh, Andre C., Bankar, Aniket, Richard-Carpentier, Guillaume, Sibai, Hassan, Yee, Karen, Davidson, Marta, Chan, Steven M., Gupta, Vikas, Maze, Dawn

Get full text

Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy by Chang, Hong, Schimmer, Aaron D

“…Livin, also called melanoma inhibitor of apoptosis protein (IAP) or kidney IAP, is a member of the IAP family of caspase inhibitors that selectively binds the…”
Get full text

The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma by Xu, G. Wei, Ali, Mohsin, Wood, Tabitha E., Wong, Derek, Maclean, Neil, Wang, Xiaoming, Gronda, Marcela, Skrtic, Marko, Li, Xiaoming, Hurren, Rose, Mao, Xinliang, Venkatesan, Meenakshi, Zavareh, Reza Beheshti, Ketela, Troy, Reed, John C., Rose, David, Moffat, Jason, Batey, Robert A., Dhe-Paganon, Sirano, Schimmer, Aaron D.

“…The proteasomal pathway of protein degradation involves 2 discrete steps: ubiquitination and degradation. Here, we evaluated the effects of inhibiting the…”
Get full text